Home > Press > Particle Sciences Develops Zero-Order-Release Combination Device Technology
Abstract:
Particle Sciences Inc. today announced the development of their "Microreservoir" technology enabling the manufacture of drug-eluting polymer medical devices that release drugs at constant rates over 30 days or more. This technology has already been used by Particles Sciences to develop drug eluting vaginal rings. "Drug release from polymeric materials often follows a burst/first-order kinetic profile which may not be clinically desired," explained Andrew Loxley, Director of New Technologies. "Traditionally the burst effect has been reduced by confining the API to a reservoir within the device, but this adds complexity and cost to production," he added. In their approach, Particle Sciences' scientists first encapsulate the drug in polymer microparticles before blending with the polymer used to make the final product. Robert Lee, VP of Pharmaceutical Development commented, "Microencapsulating the drug enabled the use of simple molding processes to fabricate devices containing tens of thousands of 'microreservoirs,' and the devices exhibit constant drug release profiles equivalent to traditional reservoir devices. This approach greatly simplifies production and adds tremendous flexibility to both single and multi-drug devices." Particle Sciences sees broad utility for this proprietary technology, which is applicable to polymer devices, films, coatings and other polymeric structures from which drugs or other materials are to be released at a constant rate.
####
About Particle Sciences Inc.
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
For more information, please click here
Contacts:
Maureen Cochran
610-861-4701
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||